These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24728953)

  • 1. Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia.
    Cicero AF; Reggi A; Parini A; Morbini M; Rosticci M; Grandi E; Borghi C
    High Blood Press Cardiovasc Prev; 2014 Sep; 21(3):221-6. PubMed ID: 24728953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study.
    Cicero AF; Derosa G; Pisciotta L; Barbagallo C;
    J Med Food; 2015 Nov; 18(11):1270-3. PubMed ID: 26274827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk.
    Martinez-Martin F; Corbella E; Sarasa I; Trias F; Petitbò D; Licerán M; Sánchez-Hernández RM; Martin D; Sánchez A; Arnás C; de Dios S; Florido M; Pintó X
    Semergen; 2022 Sep; 48(6):403-410. PubMed ID: 35606250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination.
    Cullberg G; Hamberger L; Mattsson LA; Mobacken H; Samsioe G
    Acta Obstet Gynecol Scand; 1985; 64(3):203-7. PubMed ID: 3160212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients.
    Formisano E; Pasta A; Cremonini AL; Favari E; Ronca A; Carbone F; Semino T; Di Pierro F; Sukkar SG; Pisciotta L
    J Med Food; 2020 Jun; 23(6):658-666. PubMed ID: 31663806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial.
    Galletti F; Fazio V; Gentile M; Schillaci G; Pucci G; Battista F; Mercurio V; Bosso G; Bonaduce D; Brambilla N; Vitalini C; D'Amato M; Giacovelli G
    Lipids Health Dis; 2019 Mar; 18(1):66. PubMed ID: 30885221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study.
    Battaglia C; Mancini F; Fabbri R; Persico N; Busacchi P; Facchinetti F; Venturoli S
    Fertil Steril; 2010 Sep; 94(4):1417-1425. PubMed ID: 19591981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of monacolin K-containing nutraceutical on cholesterol homeostasis re-establishment and CVD risk reduction in hypercholesterolemic subjects.
    Gojkovic T; Vladimirov S; Kotur-Stevuljevic J; Bogavac-Stanojevic N; Zeljkovic A; Vekic J; Antonic T; Spasojevic-Kalimanovska V
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5261-5267. PubMed ID: 34486702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.
    Pisciotta L; Bellocchio A; Bertolini S
    Lipids Health Dis; 2012 Sep; 11():123. PubMed ID: 22998978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
    Glintborg D; Sidelmann JJ; Altinok ML; Mumm H; Andersen M
    Metabolism; 2015 Oct; 64(10):1272-8. PubMed ID: 26194691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
    Chen MJ; Yang WS; Chen HF; Kuo JJ; Ho HN; Yang YS; Chen SU
    Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
    Harmanci A; Cinar N; Bayraktar M; Yildiz BO
    Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
    Yildizhan R; Gokce AI; Yildizhan B; Cim N
    Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].
    Zhang J; Su M; Xu L; Yang Z; Yin W; Nie Y; Qiao X; Cheng R; Ma Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul; 38(8):917-922. PubMed ID: 30187872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.